118.92
9.17 (8.36%)
| Previous Close | 109.75 |
| Open | 123.00 |
| Volume | 5,008,976 |
| Avg. Volume (3M) | 1,586,858 |
| Market Cap | 11,765,730,304 |
| Price / Earnings (TTM) | 33.31 |
| Price / Earnings (Forward) | 21.46 |
| Price / Sales | 5.21 |
| Price / Book | 4.74 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 14.49% |
| Operating Margin (TTM) | 20.87% |
| Diluted EPS (TTM) | 3.29 |
| Quarterly Revenue Growth (YOY) | 21.80% |
| Quarterly Earnings Growth (YOY) | -30.20% |
| Total Debt/Equity (MRQ) | 19.14% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | 595.40 M |
| Levered Free Cash Flow (TTM) | 457.98 M |
| Return on Assets (TTM) | 10.45% |
| Return on Equity (TTM) | 14.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 99.17% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 185.00 (Evercore ISI Group, 55.57%) | Buy |
| Median | 154.00 (29.50%) | |
| Low | 115.00 (BMO Capital, -3.30%) | Hold |
| Average | 156.09 (31.26%) | |
| Total | 10 Buy, 1 Hold | |
| Avg. Price @ Call | 109.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 06 May 2025 | 115.00 (-3.30%) | Hold | 109.68 |
| Canaccord Genuity | 06 May 2025 | 160.00 (34.54%) | Buy | 109.68 |
| 28 Apr 2025 | 158.00 (32.86%) | Buy | 106.46 | |
| Guggenheim | 06 May 2025 | 165.00 (38.75%) | Buy | 109.68 |
| 10 Feb 2025 | 163.00 (37.07%) | Buy | 118.81 | |
| Needham | 06 May 2025 | 139.00 (16.89%) | Buy | 109.68 |
| 15 Apr 2025 | 138.00 (16.04%) | Buy | 96.16 | |
| Piper Sandler | 06 May 2025 | 154.00 (29.50%) | Buy | 109.68 |
| RBC Capital | 06 May 2025 | 145.00 (21.93%) | Buy | 109.68 |
| 14 Apr 2025 | 137.00 (15.20%) | Buy | 94.89 | |
| UBS | 06 May 2025 | 152.00 (27.82%) | Buy | 109.68 |
| 04 Apr 2025 | 137.00 (15.20%) | Buy | 95.65 | |
| Evercore ISI Group | 24 Apr 2025 | 185.00 (55.57%) | Buy | 105.76 |
| HC Wainwright & Co. | 22 Apr 2025 | 168.00 (41.27%) | Buy | 101.74 |
| 24 Feb 2025 | 185.00 (55.57%) | Buy | 119.11 | |
| JP Morgan | 26 Mar 2025 | 184.00 (54.73%) | Buy | 114.45 |
| Morgan Stanley | 07 Mar 2025 | 150.00 (26.14%) | Buy | 113.04 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |